63.50PLN-3.64%Mkt Cap: 147.72M $P/E: —1d ago
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap147.72M $
Enterprise Value—
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-5.99M $
Revenue/Share—
Last Price63.50 PLN
Fiscal Year End—
MR Quarter—
Employees—
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLSNBIO00013
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-2.71
EPS (Forward)—
52W Range
26.2053% of range96.60
52W High96.60 PLN
52W Low26.20 PLN
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-141.89%
ROA-90.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.12M $
CapEx (TTM)222.41K $
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)31.00 PLN
Upside (mean)-51.2%
Target Range31.00 PLN – 31.00 PLN
# Analysts1
Ownership
Shares Out.8.73M
Float—
Insiders39.79%
Institutions8.45%
Technical
SMA 5058.82 (+7.9%)
SMA 20047.94 (+32.4%)
Beta—
S&P 52W Chg19.97%
Avg Vol (30d)87.07K
Avg Vol (10d)32.42K
Technical Indicators
RSI (14)51.0
MACD1.6179
MACD Signal2.8872
MACD Hist.-1.2693
BB Upper75.14 PLN
BB Middle68.68 PLN
BB Lower62.22 PLN
BB Width18.81%
ATR (14)4.947 PLN
Vol Ratio (20d)0.36x